The MINDACT trial: The first prospective clinical validation of a genomic tool

被引：91
作者：
Cardoso, Fatima [1 ]
Piccart-Gebhart, Martine [1 ]
Van't Veer, Laura [2 ]
Rutgers, Emiel [3 ]
机构：
[1] Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium
[2] Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Surg, Amsterdam, Netherlands
来源：
MOLECULAR ONCOLOGY | 2007年 / 1卷 / 03期
关键词：
MINDACT; MammaPrint (TM); Genomics; Breast cancer; 70-gene profiler;
D O I：
10.1016/j.molonc.2007.10.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
One of the main challenges in oncology today has become to distinguish accurately between those patients who need adjuvant treatment and those who do not. This, together with the identification of the best type of therapy for the individual patient and the development of drugs targeting specific characteristics of tumour cells, are the goals of treatment tailoring or personalized medicine. The MINDACT trial (Microarray In Node negative Disease may Avoid ChemoTherapy) was recently launched with the aim of prospectively validating the superior performance of a new prognostic RNA-based tool - the Amsterdam 70-gene profiler MammaPrint (TM), in order to implement its use in clinical practice later on. This manuscript shortly reviews the rational, design and logistics of MINDACT. (C) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码：246 / 251
页数：6
相关论文
共 23 条
[1]  
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[2]   Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools [J].
Ach, Robert A. ;
Floore, Arno ;
Curry, Bo ;
Lazar, Vladimir ;
Glas, Annuska M. ;
Pover, Rob ;
Tsalenko, Anya ;
Ripoche, Hugues ;
Cardoso, Fatima ;
d'Assignies, Mahasti Saghatchian ;
Bruhn, Laurakay ;
Van't Veer, Laura J. .
BMC GENOMICS, 2007, 8 (1)
[3]   Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial [J].
Bogaerts, Jan ;
Cardoso, Fatima ;
Buyse, Marc ;
Braga, Sofia ;
Loi, Sherene ;
Harrison, Jillian A. ;
Bines, Jacques ;
Mook, Stella ;
Decker, Nuria ;
Ravdin, Peter ;
Therasse, Patrick ;
Rutgers, Emiel ;
van't Veer, Laura J. ;
Piccart, Martine .
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (10) :540-551
[4]   Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer [J].
Buyse, Marc ;
Loi, Sherene ;
van't Veer, Laura ;
Viale, Giuseppe ;
Delorenzi, Mauro ;
Glas, Annuska M. ;
d'Assignies, Mahasti Saghatchian ;
Bergh, Jonas ;
Lidereau, Rosette ;
Ellis, Paul ;
Harris, Adrian ;
Bogaerts, Jan ;
Therasse, Patrick ;
Floore, Arno ;
Amakrane, Mohamed ;
Piette, Fanny ;
Rutgers, Emiel ;
Sotiriou, Christos ;
Cardoso, Fatima ;
Piccart, Martine J. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (17) :1183-1192
[5]  
CARDOSO F, J CLIN ONCO IN PRESS
[6]  
*CLINICALTRIALS GO, ID NCT00017095
[7]  
*CLINICALTRIALS GO, ID NCT00310180
[8]  
DEMESQUITA JMB, 2005, BREAST CANC RES T S1, V94, pA309
[9]   Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series [J].
Desmedt, Christine ;
Piette, Fanny ;
Loi, Sherene ;
Wang, Yixin ;
d'assignies, Mahasti Saghatchian ;
Bergh, Jonas ;
Lidereau, Rosette ;
Ellis, Paul ;
Harris, Adrian L. ;
Klijn, Jan G. M. ;
Foekens, John A. ;
Cardoso, Fatima ;
Piccart, Martine J. ;
Buyse, Marc ;
Sotiriou, Christos .
CLINICAL CANCER RESEARCH, 2007, 13 (11) :3207-3214
[10]   Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer [J].
Foekens, JA ;
Atkins, D ;
Zhang, Y ;
Sweep, FCGJ ;
Harbeck, N ;
Paradiso, A ;
Cufer, T ;
Sieuwerts, AM ;
Talantov, D ;
Span, PN ;
Tjan-Heijnen, VCG ;
Zito, AF ;
Specht, K ;
Hoefler, H ;
Golouh, R ;
Schittulli, F ;
Schmitt, M ;
Beex, LVAM ;
Klijn, IGM ;
Wang, YX .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (11) :1665-1671
123